EUCTR2008-005065-64-DE进行中（未招募）不适用
A multicenter, double-blind, randomized, placebo-controlled, two-arm parallel-group study of BGG492 as monotherapy in individuals with refractory partial seizures undergoing inpatient evaluation for epilepsy surgery
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects aged 18 to 65 years
- •2. A diagnosis of partial seizures (with or without secondary generalization) and undergoing an evaluation for epilepsy surgery, based on the classification of the International League Against Epilepsy (ILAE), as modified in 1981.
- •3. A stable dosing regimen with no more than two (except of association of Lamotrigine with Valproate) antiepileptic drugs (AED) prior to randomization. (Note: allowed AEDs at baseline are: Valproate, Lacosamide, Lamotrigine, Levetiracetam, Carbamazepine, Oxcarbazepine, Phenytoin, Clobazam, Topiramate, Pregabalin, Gabapentin)
- •4. Willing to be hospitalized for a pre-surgical evaluation and study procedures for up to 10 days.
- •5. Absence of evolving space-occupying lesions or progressive neurological diseases.
- •6. Capable of communicating well with the Investigator, understanding and complying with the requirements of the study, satisfying the requirements of the protocol and having understood and signed the written informed consent prior to initiation of any study procedure after the nature of the study has been fully explained.
- •7. At Screening, and Baseline, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in the sitting position after the subject has rested for at least three (3) minutes, and again when required after three (3) minutes in the standing position.
- •8. Female subjects of childbearing potential must have an established use of oral, injected or implanted hormonal methods of contraception or use two acceptable methods of contraception, (e.g., intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening and for the entire duration of the study.
- •Periodic abstinence and withdrawal are not acceptable methods of contraception.
- •Proof that a discussion has taken place with the Investigator / Nurse has to be
- •captured as source document.
- •9. Postmenopausal females must have had no regular menstrual bleeding for at least one (1) year prior to screening. Menopause should be confirmed objectively (such as by serum FSH level of = 40 IU/L). OR: Female subjects who report surgical sterilization must have had the procedure at least six (6) months prior to the initial dosing. Surgical sterilization and hysterectomy procedures must be supported with clinical documentation made available to Sponsor and noted in the Relevant Medical History / Current Medical Conditions section of the CRF.
- •10. All female subjects must have negative pregnancy test results at screening and baseline.
- •11. Male subjects must be using a double-method local contraception, (e.g. spermicidal gel plus condom) for the entire duration of the study.
- •12. Subjects must weigh at least 50 kg to participate in this study and must have a body mass index (BMI) within the range of 18 to 35.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnant or nursing females.
- •2. A diagnosis of generalized seizures (with the exception of secondarily generalized seizures), based on the classification of the International League Against Epilepsy (ILAE), as modified in 1981.
- •3. A history of frequent and/or severe status epilepticus (i.e. requiring intensive care unit treatment).
- •4. Current treatment with phenobarbital, primidone or zonisamide
- •5. Having discontinued chronic benzodiazepine and barbiturate therapy within 30 days prior to the baseline.
- •6. Having electrodes implanted in the brain.
- •7. Experiencing pseudo-seizures that may impact the interpretation of seizures observed during the study.
- •8. Having evidence on physical examination, or a history of any medically significant thyroid, cardiac, respiratory, hepatic, gastrointestinal, renal, hematologic, oncologic, psychiatric or progressive neurological disorder, requiring current medical intervention/therapy likely to have a significant impact on the outcome of this study.
- •9. Malignancy, or a history of malignancy, within the past five (5) years.
- •10. With a history of clinically significant drug allergy or a known hypersensitivity to drugs of the same class to the study drug.
- •11. With any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs, e.g. GI surgery and/or pancreatic or liver disease
- •12. Having one or more clinically relevant abnormal biochemical or haematological variables or having liver function tests exceeding three times the upper limit of normal values.
- •13. With evidence or history of drug or alcohol abuse in the three (3) months preceding Screening, or evidence of such abuse as indicated by the laboratory assays conducted during Screening or Baseline.
- •14. With mental impairment limiting the ability to comply with study requirements.
- •15. Patient under treatment of Lamotrigine in combination with Valproate
- •16. Patients using (or having used within four (4) weeks before initial dosing) concomitant medications that are potent inhibitors of CYP3A4 (e.g., ketoconazole, ritonavir, etc.) and Pgp (P-glycoprotein) (e.g. verapamil). See Appendix 2 for a list of medications that are not allowed during the study.
- •17. Patients using (or having used within four (4) weeks before initial dosing) concomitant medications that are potent inducers of CYP3A4 and Pgp (P-glycoprotein) (e.g. Rifampin St John’s wort), except carbamazepine, oxcarbamazepine and phenytoin. See Appendix 2 for a list of medications that are not allowed during the study.
- •18. Having participated in any clinical investigation within four (4) weeks prior to initial dosing or longer if required by local regulations, and for any other limitation of participation based on local regulations.
- •19. Having donated or lost 400 mL or more of blood and/or blood components within eight (8) weeks prior to initial dosing, or longer if required by local regulation.
- •20. Having a significant illness other than epilepsy within two (2) weeks prior to initial dosing.
- •21. Having a medical history of clinically significant ECG abnormalities or a family history (grandparents, parents and siblings) of a prolonged QT-interval syndrome (as far as is known).
- •22. Having recent (within the last three (3) years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting, palpitations, etc).
- •23. Having a history of immunodeficiency diseases, including a positive HIV (E
研究者
相似试验
进行中（未招募）
1 期
Efficacy and Safety of apraglutide in short bowel syndrome and intestinal failureEUCTR2020-001202-32-NOVectivBio AG164
进行中（未招募）
1 期
A research study to study the effects of a new oral drug called lucerastat in adults with Fabry diseaseFabry diseaseMedDRA version: 20.0Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-003369-85-NLIdorsia Pharmaceuticals Ltd99
进行中（未招募）
1 期
A research study to study the effects of a new oral drug called lucerastat in adults with Fabry diseaseFabry diseaseMedDRA version: 20.0Level: PTClassification code 10016016Term: Fabry's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-003369-85-GBIdorsia Pharmaceuticals Ltd99
进行中（未招募）
不适用
A multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and tolerability of AVE5530 when added to ongoing stable statin therapy at high doses in patients with severe primary hypercholesterolemiaPrimary HypercholesterolemiaMedDRA version: 11.0Level: LLTClassification code 10060375Term: <Manually entered code. Term in E.1.1>EUCTR2008-002849-23-BESanofi-Aventis Recherche & Développement668
进行中（未招募）
不适用
A multicenter, double-blind, randomized, placebo-controlled, 4 parallel groups, dose-ranging trial evaluating the efficacy and safety of ucb 34714 used as adjunctive treatment at doses of 50, 150 and 400 mg/day in b.i.d. administration (oral capsules of 25 or 50 mg) for a maximum of 13 weeks in subjects from 16 to 65 years with refractory epilepsy suffering from partial onset seizures whether or not secondarily generalized - ucb 34714 dose-rangingEUCTR2004-001856-35-FICB S.A. Pharma Sector245